Austin director joins Prima board
28 March, 2002 by Tanya HollisImmunologist Prof Mark Hogarth has been appointed to the board of Melbourne biotech Prima Biomed.
GroPep looks to sell off neuropathy research
28 March, 2002 by Tanya HollisGroPep is hoping to license out its research into a topical treatment for diabetic neuropathy after product development studies failed to come up with a suitable transdermal formulation.
Biologist takes up attorney role
28 March, 2002 by Tanya HollisA molecular geneticist has joined Freehills Carter Smith Beadle's biotechnology group as a patent attorney.
Autogen poised for Nasdaq listing
26 March, 2002 by Tanya HollisMelbourne gene discovery company Autogen has moved a step closer to listing on Nasdaq with the appointment of a strategic and corporate advisor in the United States.
The PM's advisers for science
25 March, 2002 by Pete YoungA consummate politician he may be, but John Howard is no scientist.
Inhalix rethinks after funding crunch
25 March, 2002 by Daniella GoldbergPromising medical device start-up company Inhalix has reassessed its strategy and has temporarily parked the company while it reviews its future options, according to CEO Graeme Woodrow.
Careers outlook broadens for biotech professionals
25 March, 2002 by Daniella GoldbergA range of employment opportunities is opening up for fledglings of the biotechnology industry as well as for young entrepreneurial scientists returning from overseas.
Sutherland retires to pursue biotech
25 March, 2002 by Melissa TrudingerProfessor Grant Sutherland, one of Australia's leading geneticists, is retiring as the director of the Department of Cytogenetics and Molecular Genetics at the Women's and Children's Hospital in Adelaide.
Showing Australian companies to the US
22 March, 2002 by Daniella GoldbergA significant number of Australian and New Zealand Biotech companies will showcase their wares to business angels and venture capitalists in San Fransisco mid-year.
VCs name their bioinformatic hot buttons
21 March, 2002 by Malorye BrancaVenture capitalists are hungry for systems biology, data mining, and anything that targets "where the rat is in the snake," said James Sherblom, chairman and managing partner of Seaflower Ventures Inc, speaking at the biotech financing round table held on March 14 at the BioITWorld Conference and Expo in Boston.
Interview: Life science 'the next big thing, says IBM's Kovac
21 March, 2002 by Staff WritersIDG spoke with Dr Caroline Kovac, general manager of IBM Life Sciences Solutions, about her company's involvement in the life sciences.
Bridging the communications gap between bucks and biology
20 March, 2002 by Staff WritersFor an industry that's touted as the way forward for Australia's economy, there can be a surprising lack of clarity or consistency of views about the biotech sector's prognosis.
Queensland institutes in the hiring line
20 March, 2002 by Pete YoungQueensland's biotech employment outlook is bright courtesy of a State government committed to pumping hundreds of millions of dollars into bioindustry over 10 years.
No headlong rush, but biotechs still aiming for market
20 March, 2002 by Tanya HollisBiotech newcomers have been a rare event on the Australian bourse in the past six months.
New Fed science committee
20 March, 2002 by Iain ScottA new standing committe on science and technology has been announced by the Federal government.
